NICE Medtech Innovation Briefings are a product from NICE to support NHS and social care commissioners and staff who are considering using new medical devices and other medical technologies or diagnostic technologies. The information provided includes a description of the technology, how it’s used and its potential role in the treatment pathway.
NICE Medtech Innovation briefings also include a review of relevant published evidence and the likely costs of using the technology, but they are not NICE guidance and do not make any recommendations on the value of using the technologies. Whether or not to use the products described is entirely the choice of local staff. The briefings will help avoid the need for organisations to produce similar information, so saving staff time, effort and resources.
The latest Medtech Innovation Briefings to be published are:
· UrgoStart for chronic wounds (MIB82)
The UrgoStart wound dressing is used to treat chronic wounds such as diabetic foot ulcers, pressure ulcers or venous leg ulcers, as well as non-healing acute wounds. It uses a technology that the manufacturer claims promotes faster healing in chronic wounds by inhibiting proteases in the wound and stabilising growth factors.
· Woundchek Protease Status for assessing elevated protease status in chronic wounds (MIB83)
The Woundchek Protease Status point-of-care diagnostic test is designed to qualitatively assess protease activity in chronic wounds, in order to guide treatment. It would be used by clinical staff treating chronic wounds, to aid decision-making on wound dressings. Protease modulating dressings could be chosen for wounds where elevated protease status is detected.
NICE Medtech Innovation Briefings are commissioned by NHS England and produced in support of the NHS 5 Year Forward View, specifically as one of a number of steps which will accelerate innovation in new treatments and diagnostics. It’s hoped that this impartial information about innovative devices and diagnostics will help NHS and social care professionals, and buyers and commissioners of services and with their local decision-making. Medtech Innovation Briefings are available at http://www.nice.org.uk/advice?type=mib .
About the Medical Technologies Evaluation Programme
The Medical Technologies Evaluation Programme focuses specifically on the evaluation of innovative medical technologies, including devices and diagnostics. The types of products which might be included are medical devices that deliver treatment such as those implanted during surgical procedures, technologies that give greater independence to patients, and diagnostic devices or tests used to detect or monitor medical conditions. The independent Medical Technology Advisory Committee has two core remits: selecting medical technologies for evaluation by NICE guidance programmes and also developing medical technologies guidance itself. The guidance applies to the NHS in England, and is not mandatory.
More information is available at http://www.nice.org.uk/MT.
The National Institute for Health and Care Excellence (NICE) is the independent body responsible for driving improvement and excellence in the health and social care system. We develop guidance, standards and information on high-quality health and social care. We also advise on ways to promote healthy living and prevent ill health.
Our aim is to help practitioners deliver the best possible care and give people the most effective treatments, which are based on the most up-to-date evidence and provide value for money, in order to reduce inequalities and variation.
Our products and resources are produced for the NHS, local authorities, care providers, charities, and anyone who has a responsibility for commissioning or providing healthcare, public health or social care services.
To find out more about what we do, visit our website: www.nice.org.uk and follow us on Twitter: @NICEComms.
The information contained in this message and any attachments is intended for the addressee(s) only. If you are not the addressee, you may not disclose, reproduce or distribute this message. If you have received this message in error, please advise the sender and delete it from your system. Any personal data sent in reply to this message will be used in accordance with provisions of the Data Protection Act 1998 and only for the purposes of the Institute's work.
All messages sent by NICE are checked for viruses, but we recommend that you carry out your own checks on any attachment to this message. We cannot accept liability for any loss or damage caused by software viruses.